Citations

Clear

3314 citation(s) found for "Yu, Alexander".

Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies
Ansell, Stephen M. , Maris, Michael B., Lesokhin, Alexander M. , Chen, Robert W., Flinn, Ian W. , Sawas, Ahmed , Minden, Mark D. , Villa, Diego , Percival, Mary‐Elizabeth M. , Foran, James M. , Mei, Matthew , Zain, Jasmine , Akilov, Oleg E. , Johnson, Lisa D. , Catalano, Tina, Petrova, Penka S., Uger, Robert A. , Milea, Anca, Roberge, Kathleen, Shou, Yaping, O’Connor, Owen A. , Mei, Matthew , Akilov, Oleg E , Johnson, Lisa D S , Sievers, Eric L , Lesokhin, Alexander M , Flinn, Ian W , Advani, Anjali S. , Horwitz, Steven M. , Savage, Kerry J. , Querfeld, Christiane , Sievers, Eric L.

Mayo Clinic

Clinical Cancer Research | January 15, 2021 | Volume: 27 | Issue: 8 | Pages: 2190-2199

10.1158/1078-0432.ccr-20-3706 | PMID 33451977 Get It

Abstract Purpose: TTI-621 (SIRPα-IgG1 Fc) is a novel checkpoint inhibitor that activates antitumor activity by blocking the CD47 “don't eat me” signal. This first-in-human phase I study (NCT02663518) evaluated the safety and activity of TTI-621 in relapsed/refractory (R/R) hematologic malignancies. Patients and Methods: Patients with R/R lymphoma received escalating weekly intravenous TTI-621 to determine the maximum tolerated dose (MTD). During expansion, patients with various malignancies received weekly single-agent TTI-621 at the MTD; TTI-621 was combined with rituximab in patients with B-cell non-Hodgkin lymphoma (B-NHL) or with nivolumab in patients with Hodgkin lymphoma. The primary endpoint was the incidence/severity of adverse events (AEs). Secondary endpoint included overall response rate (ORR). Results: Overall, 164 patients received TTI-621: 18 in escalation and 146 in expansion (rituximab combination, n = 35 and nivolumab combination, n = 4). On the basis of transient grade 4 thrombocytopenia, the MTD was determined as 0.2 mg/kg; 0.1 mg/kg was evaluated in combination cohorts. AEs included infusion-related reactions, thrombocytopenia, chills, and fatigue. Thrombocytopenia (20%, grade ≥3) was reversible between doses and not associated with bleeding. Transient thrombocytopenia that determined the initial MTD may not have been dose limiting. The ORR for all patients was 13%. The ORR was 29% (2/7) for diffuse large B-cell lymphoma (DLBCL) and 25% (8/32) for T-cell NHL (T-NHL) with TTI-621 monotherapy and was 21% (5/24) for DLBCL with TTI-621 plus rituximab. Further dose optimization is ongoing. Conclusions: TTI-621 was well-tolerated and demonstrated activity as monotherapy in patients with R/R B-NHL and T-NHL and combined with rituximab in patients with R/R B-NHL.
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)
Liu, Stephen V. , Reck, Martin , Mansfield, Aaron S. , Mok, Tony , Scherpereel, Arnaud , Garassino, Marina Chiara , Castro, Javier de , Nishio, Makoto , Orlandi, Francesco , Alatorre-Alexander, Jorge , Leal, Ticiana , Cheng, Ying , Lam, Sivuonthanh, McCleland, Mark L., Phan, See, Horn, Leora , De Castro Carpeno, Javier , Nishio, Makoto , Leal, Ticiana , Cheng, Ying , Horn, Leora , Mansfield, Aaron S , Liu, Stephen V , Reinmuth, Niels , Califano, Raffaele , Lee, Jong-Seok, Deng, Yu Lin

Mayo Clinic

Journal of Clinical Oncology | January 13, 2021 | Volume: 39 | Issue: 6 | Pages: 619-630

10.1200/jco.20.01055 | PMID 33439693 Get It

PURPOSE: IMpower133 (ClinicalTrials.gov identifier: NCT02763579 ), a randomized, double-blind, phase I/III study, demonstrated that adding atezolizumab (anti-programmed death-ligand 1 [PD-L1]) to carboplatin plus etoposide (CP/ET) for first-line (1L) treatment of extensive-stage small-cell lung cancer (ES-SCLC) resulted in significant improvement in overall survival (OS) and progression-free survival (PFS) versus placebo plus CP/ET. Updated OS, disease progression patterns, safety, and exploratory biomarkers (PD-L1, blood-based tumor mutational burden [bTMB]) are reported. PATIENTS AND METHODS: Patients with untreated ES-SCLC were randomly assigned 1:1 to receive four 21-day cycles of CP (area under the curve 5 mg per mL/min intravenously [IV], day 1) plus ET (100 mg/m 2 IV, days 1-3) with atezolizumab (1,200 mg IV, day 1) or placebo, and then maintenance atezolizumab or placebo until unacceptable toxicity, disease progression, or loss of clinical benefit. Tumor specimens were collected; PD-L1 testing was not required for enrollment. The two primary end points, investigator-assessed PFS and OS, were statistically significant at the interim analysis. Updated OS and PFS and exploratory biomarker analyses were conducted. RESULTS: Patients received atezolizumab plus CP/ET (n = 201) or placebo plus CP/ET (n = 202). At the updated analysis, median follow-up for OS was 22.9 months; 302 deaths had occurred. Median OS was 12.3 and 10.3 months with atezolizumab plus CP/ET and placebo plus CP/ET, respectively (hazard ratio, 0.76; 95% CI, 0.60 to 0.95; descriptive P = .0154). At 18 months, 34.0% and 21.0% of patients were alive in atezolizumab plus CP/ET and placebo plus CP/ET arms, respectively. Patients derived benefit from the addition of atezolizumab, regardless of PD-L1 immunohistochemistry or bTMB status. CONCLUSION: Adding atezolizumab to CP/ET as 1L treatment for ES-SCLC continued to demonstrate improved OS and a tolerable safety profile at the updated analysis, confirming the regimen as a new standard of care. Exploratory analyses demonstrated treatment benefit independent of biomarker status.
Placental growth factor promotes tumour desmoplasia and treatment resistance in intrahepatic cholangiocarcinoma
Aoki, Shuichi , Inoue, Koetsu , Klein, Sebastian , Halvorsen, Stefan , Matsui, Aya , Nikmaneshi, Mohammad R. , Hato, Tai , Chen, Xianfeng , Nia, Hadi T. , Chen, Ivy, Schanne, Daniel H. , Mamessier, Émilie , Shigeta, Kohei , Ramjiawan, Rakesh R. , Schmidt, Tyge CE , Iwasaki, M, Hong, Theodore S. , Plum, Patrick Sven , Dima, Simona , Popescu, Irinel , Bardeesy, Nabeel, Munn, Lance L. , Sassi, Slim , Jain, Rakesh K., Zhu, Andrew X. , Duda, Dan G. , Shigeta, Kohei , Yau, Thomas , Duda, Dan G , Chen, Jiang , Kitahara, Shuji , Kawakubo, Kazumichi , Kikuchi, Hiroto , Iwasaki, Masaaki, Quaas, Alexander , Borad, Mitesh J. , Jain, Rakesh K.

Mayo Clinic

Gut | January 12, 2021 | Volume: 71 | Issue: 1 | Pages: 185-193

10.1136/gutjnl-2020-322493 | PMID 33431577 Get It

Objective Intrahepatic cholangiocarcinoma (ICC)—a rare liver malignancy with limited therapeutic options—is characterised by aggressive progression, desmoplasia and vascular abnormalities. The aim of this study was to determine the role of placental growth factor (PlGF) in ICC progression. Design We evaluated the expression of PlGF in specimens from ICC patients and assessed the therapeutic effect of genetic or pharmacologic inhibition of PlGF in orthotopically grafted ICC mouse models. We evaluated the impact of PlGF stimulation or blockade in ICC cells and cancer-associated fibroblasts (CAFs) using in vitro 3-D coculture systems. Results PlGF levels were elevated in human ICC stromal cells and circulating blood plasma and were associated with disease progression. Single-cell RNA sequencing showed that the major impact of PlGF blockade in mice was enrichment of quiescent CAFs, characterised by high gene transcription levels related to the Akt pathway, glycolysis and hypoxia signalling. PlGF blockade suppressed Akt phosphorylation and myofibroblast activation in ICC-derived CAFs. PlGF blockade also reduced desmoplasia and tissue stiffness, which resulted in reopening of collapsed tumour vessels and improved blood perfusion, while reducing ICC cell invasion. Moreover, PlGF blockade enhanced the efficacy of standard chemotherapy in mice-bearing ICC. Conclusion PlGF blockade leads to a reduction in intratumorous hypoxia and metastatic dissemination, enhanced chemotherapy sensitivity and increased survival in mice-bearing aggressive ICC.
STIM1 Mediates Calcium-Dependent Epigenetic Reprogramming in Pancreatic Cancer
Kutschat, Ana P. , Hamdan, Feda H. , Wang, Xin , Wixom, Alexander Q. , Najafova, Zeynab , Gibhardt, Christine S. , Kopp, Waltraut, Gaedcke, Jochen , Ellenrieder, Volker , Heßmann, Elisabeth , Johnsen, Steven A. , Johnsen, Steven A , Najafova, Zeynab , Kutschat, Ana Patricia , Wixom, Alexander Q , Ströbel, Philipp , Bogeski, Ivan

Mayo Clinic

Cancer Research | January 12, 2021 | Volume: 81 | Issue: 11 | Pages: 2943-2955

10.1158/0008-5472.can-20-2874 | PMID 33436389 Get It

Abstract Pancreatic ductal adenocarcinoma (PDAC) displays a dismal prognosis due to late diagnosis and high chemoresistance incidence. For advanced disease stages or patients with comorbidities, treatment options are limited to gemcitabine alone or in combination with other drugs. While gemcitabine resistance has been widely attributed to the levels of one of its targets, RRM1, the molecular consequences of gemcitabine resistance in PDAC remain largely elusive. Here we sought to identify genomic, epigenomic, and transcriptomic events associated with gemcitabine resistance in PDAC and their potential clinical relevance. We found that gemcitabine-resistant cells displayed a coamplification of the adjacent RRM1 and STIM1 genes. Interestingly, RRM1, but not STIM1, was required for gemcitabine resistance, while high STIM1 levels caused an increase in cytosolic calcium concentration. Higher STIM1-dependent calcium influx led to an impaired endoplasmic reticulum stress response and a heightened nuclear factor of activated T-cell activity. Importantly, these findings were confirmed in patient and patient-derived xenograft samples. Taken together, our study uncovers previously unknown biologically relevant molecular properties of gemcitabine-resistant tumors, revealing an undescribed function of STIM1 as a rheostat directing the effects of calcium signaling and controlling epigenetic cell fate determination. It further reveals the potential benefit of targeting STIM1-controlled calcium signaling and its downstream effectors in PDAC. Significance: Gemcitabine-resistant and some naïve tumors coamplify RRM1 and STIM1, which elicit gemcitabine resistance and induce a calcium signaling shift, promoting ER stress resistance and activation of NFAT signaling.
Tissue-resident CD4 + T helper cells assist the development of protective respiratory B and CD8 + T cell memory responses
Son, Young Min , Cheon, In Su , Wu, Yue , Li, Chaofan , Wang, Zheng , Gao, Xiaochen , Takahashi, Yoshimasa , Fu, Yang-Xin , Dent, Alexander L. , Kaplan, Mark H. , Fu, Yang‐Xin , Fu, Yang-Xin , Dent, Alexander L , Kaplan, Mark H , Taylor, Justin J , Sun, Jie , Li, Chaofan , Chen, Yao , Taylor, Justin J. , Cui, Weiguo , Sun, Jie

Mayo Clinic

Science Immunology | January 8, 2021 | Volume: 6 | Issue: 55 | Pages: No page available

10.1126/sciimmunol.abb6852 | PMID 33419791 Get It

Identification of a CD4 + helper T cell population providing in situ help to B and CD8 + T cells in the respiratory mucosa.
Transition From an Open to Closed Staffing Model in the Cardiac Intensive Care Unit Improves Clinical Outcomes
Miller, P. Elliott , Chouairi, Fouad , Thomas, Alexander , Aslam, Faisal , Canavan, Maureen , Murphy, Christa, Daggula, Krishna, Metkus, Thomas S. , Vallabhajosyula, Saraschandra , Katz, Jason N. , Brennan, Joseph , Vallabhajosyula, Saraschandra , Kunitomo, Yukiko , Carnicelli, Anthony , Desai, Nihar R. , Ahmad, Tariq , Velazquez, Eric J.

Mayo Clinic

Journal of the American Heart Association | January 8, 2021 | Volume: 10 | Issue: 3 | Pages: No page available

10.1161/jaha.120.018182 | PMID 33412899 Get It

Background Several studies have shown improved outcomes in closed compared with open medical and surgical intensive care units. However, very little is known about the ideal organizational structure in the modern cardiac intensive care unit (CICU). Methods and Results We retrospectively reviewed consecutive unique admissions (n=3996) to our tertiary care CICU from September 2013 to October 2017. The aim of our study was to assess for differences in clinical outcomes between an open compared with a closed CICU. We used multivariable logistic regression adjusting for demographics, comorbidities, and severity of illness. The primary outcome was in‐hospital mortality. We identified 2226 patients in the open unit and 1770 in the closed CICU. The unadjusted in‐hospital mortality in the open compared with closed unit was 9.6% and 8.9%, respectively ( P =0.42). After multivariable adjustment, admission to the closed unit was associated with a lower in‐hospital mortality (odds ratio [OR], 0.69; 95% CI: 0.53–0.90, P =0.007) and CICU mortality (OR, 0.70; 95% CI, 0.52–0.94, P =0.02). In subgroup analysis, admissions for cardiac arrest (OR, 0.42; 95% CI, 0.20–0.88, P =0.02) and respiratory insufficiency (OR, 0.43; 95% CI, 0.22–0.82, P =0.01) were also associated with a lower in‐hospital mortality in the closed unit. We did not find a difference in CICU length of stay or total hospital charges ( P >0.05). Conclusions We found an association between lower in‐hospital and CICU mortality after the transition to a closed CICU. These results may help guide the ongoing redesign in other tertiary care CICUs.
NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021
Altman, Jessica K. , Assi, Rita, Bachiashvili, Kimo, Fathi, Amir T. , Fedorov, Kateryna, Foran, James M. , Gojo, Ivana , Goldberg, Aaron, Hall, Aric C. , Jonas, Brian A., Levine, Matthew R., Mangan, James, Mannis, Gabriel N. , Marcucci, Guido , Moriarty, Kelsey, Ali, Moaath Mustafa, Neff, Jadee , Nejati, Reza , Olin, Rebecca L. , Patel, Anand, Percival, Mary‐Elizabeth M. , Perl, Alexander E. , Pettit, Kristen, Rao, Dinesh S. , Ravandi‐Kashani, Farhad, Schwabkey, Zaker, Shallis, Rory, Stahl, Maximilian, Stone, Richard M. , Thota, Swapna, Uy, Geoffrey L., Walker, Alison, Wang, Eunice, Awotiwon, Ajibola, Roth, Sydney L., Stehman, Katie, Strickland, Stephen A. , Przespolewski, Amanda , Strickland, Stephen Anthony , Pollyea, Daniel Aaron , Assi, Rita, Bachiashvili, Kimo, Bhatt, Vijaya Raj , Fedorov, Kateryna, Goldberg, Aaron, Jonas, Brian A., Levine, Matthew R., Mangan, James, Mims, Alice S , Moriarty, Kelsey, Ali, Moaath Mustafa, Patel, Anand, Pettit, Kristen, Schwabkey, Zaker, Shallis, Rory, Stahl, Maximilian, Thota, Swapna, Uy, Geoffrey L., Walker, Alison, Wang, Eunice, Awotiwon, Ajibola, Roth, Sydney L., Stehman, Katie

Mayo Clinic

Journal of the National Comprehensive Cancer Network | January 6, 2021 | Volume: 19 | Issue: 1 | Pages: 16-27

10.6004/jnccn.2021.0002 | PMID 33406488 Get It

The NCCN Guidelines for Acute Myeloid Leukemia (AML) provide recommendations for the diagnosis and treatment of adults with AML based on clinical trials that have led to significant improvements in treatment, or have yielded new information regarding factors with prognostic importance, and are intended to aid physicians with clinical decision-making. These NCCN Guidelines Insights focus on recent select updates to the NCCN Guidelines, including familial genetic alterations in AML, postinduction or postremission treatment strategies in low-risk acute promyelocytic leukemia or favorable-risk AML, principles surrounding the use of venetoclax-based therapies, and considerations for patients who prefer not to receive blood transfusions during treatment.
Connecting Generations of Scientists in the Council on Hypertension Through Harriet Dustan
Baylis, Chris, Brown, Nancy J. , Cassis, Lisa A. , Denton, Kate M. , Joe, Bina , Lerman, Lilach O. , Oparil, Suzanne , Reckelhoff, Jane F. , Sandberg, Kathryn , Brown, Nancy J , Watts, Stephanie W. , Alexander, Barbara T. , Touyz, Rhian M. , Denton, Kate M

Mayo Clinic

Hypertension | January 4, 2021 | Volume: 77 | Issue: 2 | Pages: 296-307

10.1161/hypertensionaha.120.16623 | PMID 33390045 Get It

Gain-of-Function Variant p.Pro2555Arg of von Willebrand Factor Increases Aggregate Size through Altering Stem Dynamics
Chen, Po‐Chia , Xu, Emma-Ruoqi , Tischer, Alexander , Klemm, Ulrike, Meß, Christian , Obser, Tobias, Kutzki, Fabian, König, Gesa, Denis, Cécile V. , Wilmanns, Matthias , Schneider, Stefan W. , Schneppenheim, Reinhard , Hennig, Janosch , Brehm, Maria A. , Auton, Matthew , Xu, Emma-Ruoqi , Wilmanns, Matthias , Tischer, Alexander , Huck, Volker , Aponte-Santamaria, Camilo A. , Gräter, Frauke

Mayo Clinic

Thrombosis and Haemostasis | January 1, 2021 | Volume: 122 | Issue: 02 | Pages: 226-239

10.1055/a-1344-4405 | PMID 33385180 Get It

AbstractThe multimeric plasma glycoprotein (GP) von Willebrand factor (VWF) is best known for recruiting platelets to sites of injury during primary hemostasis. Generally, mutations in the VWF gene lead to loss of hemostatic activity and thus the bleeding disorder von Willebrand disease. By employing cone and platelet aggregometry and microfluidic assays, we uncovered a platelet GPIIb/IIIa-dependent prothrombotic gain of function (GOF) for variant p.Pro2555Arg, located in the C4 domain, leading to an increase in platelet aggregate size. We performed complementary biophysical and structural investigations using circular dichroism spectra, small-angle X-ray scattering, nuclear magnetic resonance spectroscopy, molecular dynamics simulations on the single C4 domain, and dimeric wild-type and p.Pro2555Arg constructs. C4-p.Pro2555Arg retained the overall structural conformation with minor populations of alternative conformations exhibiting increased hinge flexibility and slow conformational exchange. The dimeric protein becomes disordered and more flexible. Our data suggest that the GOF does not affect the binding affinity of the C4 domain for GPIIb/IIIa. Instead, the increased VWF dimer flexibility enhances temporal accessibility of platelet-binding sites. Using an interdisciplinary approach, we revealed that p.Pro2555Arg is the first VWF variant, which increases platelet aggregate size and shows a shear-dependent function of the VWF stem region, which can become hyperactive through mutations. Prothrombotic GOF variants of VWF are a novel concept of a VWF-associated pathomechanism of thromboembolic events, which is of general interest to vascular health but not yet considered in diagnostics. Thus, awareness should be raised for the risk they pose. Furthermore, our data implicate the C4 domain as a novel antithrombotic drug target.
Neuromuscular ultrasound competency assessment: Consensus‐based survey
Tawfik, Eman A. , Cartwright, Michael S. , Grimm, Alexander , Boon, Andrea J. , Kerasnoudis, Antonios , Preston, David C. , Axer, Hubertus , Hobson‐Webb, Lisa D., Crump, Nicholas , Inkpen, Peter, Mandeville, Ross , Sakamuri, Sarada, Shook, Steven J. , Shin, Susan , Walker, Francis O. , Crump, Nicholas , Shin, Susan , Wilder‐Smith, Einar , Alfen, Nens van , Shahrizaila, Nortina

Mayo Clinic

Muscle & Nerve | December 31, 2020 | Volume: 63 | Issue: 5 | Pages: 651-656

10.1002/mus.27163 | PMID 33382094 Get It

AbstractNeuromuscular ultrasound is a rapidly evolving specialty with direct application for patient care. Competency assessment is an essential standard needed to ensure quality for practitioners, particularly for those newly acquiring skills with the technique. Our aim was to survey experts' opinions regarding physician competency assessment of neuromuscular ultrasound and to identify minimal competency of knowledge and skills. The opinions of 18 experts were obtained through the Delphi method using two consecutive electronic surveys. A high degree of consensus was achieved on items regarding framework and the conduct of neuromuscular ultrasound assessment and the knowledge and skills that a candidate needs to attain minimal competency in neuromuscular ultrasound. In this study, a group of neuromuscular ultrasound experts developed a general framework for neuromuscular ultrasound competency assessment and recommended testable areas of knowledge and skills suitable for establishing minimal competency.